[go: up one dir, main page]

IS5778A - Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar - Google Patents

Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar

Info

Publication number
IS5778A
IS5778A IS5778A IS5778A IS5778A IS 5778 A IS5778 A IS 5778A IS 5778 A IS5778 A IS 5778A IS 5778 A IS5778 A IS 5778A IS 5778 A IS5778 A IS 5778A
Authority
IS
Iceland
Prior art keywords
mutants
virus
human hepatitis
hepatitis
human
Prior art date
Application number
IS5778A
Other languages
English (en)
Inventor
Jin Oon Chong
Keow Lim Gek
Zhao Yi
Ning Chen Wei
Original Assignee
Government Of The Republic Of Singapore, Ministryof Health, College Of Medicine Building
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Republic Of Singapore, Ministryof Health, College Of Medicine Building filed Critical Government Of The Republic Of Singapore, Ministryof Health, College Of Medicine Building
Publication of IS5778A publication Critical patent/IS5778A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IS5778A 1998-06-19 2000-12-19 Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar IS5778A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG1998/000046 WO1999066048A1 (en) 1998-06-19 1998-06-19 A mutant human hepatitis b viral strain and uses thereof

Publications (1)

Publication Number Publication Date
IS5778A true IS5778A (is) 2000-12-19

Family

ID=20429862

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5778A IS5778A (is) 1998-06-19 2000-12-19 Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar

Country Status (22)

Country Link
US (1) US6558675B1 (is)
EP (1) EP1098981A1 (is)
JP (1) JP2002518014A (is)
KR (1) KR100498118B1 (is)
CN (1) CN1322251A (is)
AR (1) AR020093A1 (is)
AU (1) AU756866B2 (is)
BG (1) BG105066A (is)
BR (1) BR9815913A (is)
CA (1) CA2330935C (is)
HU (1) HUP0103409A3 (is)
IL (1) IL140364A0 (is)
IS (1) IS5778A (is)
MX (1) MXPA00012720A (is)
MY (1) MY118955A (is)
NO (1) NO20006456L (is)
NZ (1) NZ508890A (is)
PL (1) PL192129B1 (is)
TR (1) TR200003777T2 (is)
UA (1) UA73476C2 (is)
WO (1) WO1999066048A1 (is)
YU (1) YU80600A (is)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
SI4037708T1 (sl) 2019-09-30 2025-01-31 Gilead Sciences, Inc. Cepiva proti hbv in postopki zdravljenja hbv
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401987D0 (en) * 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
US5980901A (en) * 1996-09-18 1999-11-09 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof

Also Published As

Publication number Publication date
NO20006456D0 (no) 2000-12-18
PL345573A1 (en) 2001-12-17
WO1999066048A1 (en) 1999-12-23
PL192129B1 (pl) 2006-09-29
IL140364A0 (en) 2002-02-10
UA73476C2 (en) 2005-08-15
JP2002518014A (ja) 2002-06-25
BG105066A (en) 2001-09-28
US6558675B1 (en) 2003-05-06
MY118955A (en) 2005-02-28
HUP0103409A2 (hu) 2001-12-28
BR9815913A (pt) 2001-12-26
CN1322251A (zh) 2001-11-14
TR200003777T2 (tr) 2001-06-21
AU756866B2 (en) 2003-01-23
CA2330935A1 (en) 1999-12-23
NZ508890A (en) 2004-04-30
MXPA00012720A (es) 2002-05-08
AR020093A1 (es) 2002-04-10
NO20006456L (no) 2001-02-16
EP1098981A1 (en) 2001-05-16
HUP0103409A3 (en) 2003-10-28
YU80600A (sh) 2005-06-10
KR20010106129A (ko) 2001-11-29
CA2330935C (en) 2005-05-10
KR100498118B1 (ko) 2005-07-01
AU7795198A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
PT946323E (pt) Pos de niobio e condensadores eletroliticos de niobio
DK0935660T3 (da) Infektiöse kloner af RNA-virusser og vacciner og deraf afledte diagnostiske assays
PT773957E (pt) Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
DK2305282T3 (da) Forebyggelse og behandling af amyloidogen sygdom
NO983235L (no) Fikstur og protese innbefattende samme
DE69738197D1 (de) Azolotriazine und pyrimidine
DK1041990T3 (da) Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
NO972983D0 (no) Sulfonamider og deres anvendelse
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
FI972245A7 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
EP1694694A4 (en) REPLICATION COMPETENT HEPATITIS C-VIRUS AND METHOD OF USE
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
IS5223A (is) Lyfjasamsetningar af tizoxaníði og nitazoxaníði
DK0905128T3 (da) Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
IS5778A (is) Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar
DE60021118D1 (de) Perfluorocopolymere von tetrafluoroethylen und perfluoroalkylvinylether
DE69934810D1 (de) Neues hepatitis c viruspeptid und seine verwendung
EP1068362A4 (en) HEPATITIS C VIRUS NS5B COMPOSITIONS AND METHOD FOR THEIR USE
DK0776899T3 (da) Mellemprodukter og deres anvendelse til fremstilling af N,N'-forbundne bisindolylmaleimider
DE69934108D1 (de) Kombinierte Impfstoffe gegen Hepatitis A und Hepatitis B
NO984921D0 (no) Tienopyridinderivater og deres anvendelse